


Pharmaceutical Technology®

Pharmaceutical Technology

Guidelines for Supplement Articles – 2011

**This guide includes information about
submitting papers for publication in
Pharmaceutical Technology's single-themed issues.**



ABOUT PHARMACEUTICAL TECHNOLOGY

Pharmaceutical Technology covers all aspects of applied research and development, scale-up, and manufacturing technologies for the pharmaceutical industry. Topics include analytical testing, ingredients, formulation, drug delivery systems, information technology, manufacturing, formulation and API synthesis, packaging, outsourcing, and regulatory affairs.

We publish topical supplements on various single issues throughout the year. Topics scheduled for 2011 include:

- Preferred Providers (February)
- Solid Dosage and Excipients (April)
- Sterile Manufacturing and Bioprocessing (May)
- Outsourcing Resources (August)
- CPhI/ISCE and Ingredients (September)
- Analytical Technology and New Laboratory Testing (November)

Deadlines for Paper Proposals

Articles for supplements are typically assigned three to five months before the supplement is published. If you would like to contribute an article to a supplement, please send an outline or abstract proposal to *Pharmaceutical Technology*. If your topic is accepted for a specific special issue, an editor will assign you an official deadline for turning in the final manuscript (approximately 6 weeks before the publication date).

If your proposal is accepted for a special issue, the following guidelines will help you prepare your final paper for submission:

Consider Pharmaceutical Technology's Readers. *Pharmaceutical Technology* readers are chemists, engineers, and scientists involved in pharmaceutical manufacturing, including formulation, development, analytical testing, quality control/quality assurance, and synthesis of active ingredients. Readership also includes individuals responsible for purchasing or making purchasing decisions for machinery and equipment, as well as outsourced services. Please refer to our media kit (PharmTech.com) for a breakdown of readers' job functions. *Pharmaceutical Technology* has 38,600 BPA-qualified readers.

Accuracy and Style. Before submitting a paper, authors are urged to review manuscripts for clarity of expression, grammar, and typographical accuracy. Acronyms and abbreviations used in manuscripts should be defined on first reference and within tables and figures. The author is responsible for all statements in his or her work. All accepted manuscripts are subject to editing.

Originality and Rights. Manuscripts are reviewed with the understanding that they have not been published previously, are not ghostwritten, and are not under consideration for

publication elsewhere, including on the Internet. The author and any coauthors will be required to sign a license agreement before a manuscript is accepted for publication.

Electronic File: The paper's text should be formatted in Microsoft Word and include a cover sheet with the Title, Author and Coauthor names and affiliations, and contact information for the corresponding author. Paper titles should be short and specific and should accurately reflect the content of the article. Do not use any special text formatting codes or control characters. Strip out any special-character codes as well as any font-change codes. Please include tables and figure captions in the electronic file at the end of the article (see below for submission of actual figures and images). Beginning with the first page of the text, each page of the hard copy should be numbered consecutively.

Length. Manuscripts should be between 1800 and 2500 words. No more than 5 figures and tables combined should be submitted. Manuscripts and figures/tables that go beyond these requirements will not be accepted.

Illustrations and Figures. Original photographs, line drawings, graphs, charts, and other illustrations may be submitted in color or black and white and must be referred to in the text in consecutive order: Figure 1, Figure 2, and so forth. Be sure to include descriptive captions and credit information for all figures and images. All symbols, acronyms, and abbreviations used in figures and tables should be explained. All illustrations that do not increase the reader's understanding of the text should be omitted. In addition to the substantive figures and images provided, a four-color photograph may be used on the opening page of the article. Color photos that an author wishes to submit for consideration should be submitted with the article. All images and figures should be submitted as image files (tiff, jpeg, or eps files of at least 300 DPI.)

Tables. Original tables or charts must be identified by number (e.g., Table I, Table II) and have been created by the author (s). These can be submitted as part of the Word text file.

Illustration, Image, Figure, and Table Rights. Please note that the author must own the rights to all submitted images, tables, and figures. If a third party created and/or owns the rights to such illustrations, the author is responsible for acquiring rights permissions and providing related documentation.

Keywords, Weblinks, and Online Tools. Please provide a list of keywords relevant to the article, as well as websites or additional online references and materials that might be of interest to readers. *Pharmaceutical Technology is specifically interested in publishing video demonstrations, audio tutorials, and downloadable tools that are related to the article.* Such interactive items would be published on its website, PharmTech.com, with the full article at the same time it appears in the print magazine. Please include mention of such items, if applicable and available, when you submit your paper.

References. Literature citations in the text should be numbered consecutively indicated

by Arabic numerals in parentheses after appropriate sentences and/or paragraphs. Please do not use endnotes or footnotes. References should be grouped at the end of the manuscript and arranged in order of their appearance in the text not alphabetically. Please also be sure to style and format your references according to the guidelines provided herein. If the style and format do not adhere to our guidelines, we will return the paper to you to do so before it is accepted for publication.

Submit your paper and materials electronically to:

Michelle Hoffman,
Editorial Director
mhoffman@advanstar.com
and
Angie Drakulich,
Managing Editor
adrakulich@advanstar.com

REFERENCE GUIDELINE

Papers must use *Pharmaceutical Technology's* reference style and format below

Chapter in a book:

1. E.F. Fiese and T.A. Hagen, "Preformulation," in *Theory and Practice of Industrial Pharmacy*, L. Lachman, H.A. Lieberman, and J.L. Kanig, Eds. (Lea & Febiger, Philadelphia, PA, 3rd ed., 1986), pp. 171–194.

Article in a journal:

2. G.M. Golden, J.E. McKie, and R.O. Potts, *J. Pharm. Sci.* **76** (1), 25–28 (1987).

Published conference proceedings:

3. J.B. Dressman, Proceedings of PDA Biologics Conference (Washington, DC, 2009), PP. X-XX.

Oral presentations:

4. B.L. Hawkins, A. Baxter, and G.E. Masters, PDA Biologics Conference (Washington, DC, 2009).
5. J. Woodcock, MD, Statement, House Committee on Energy and Commerce Hearing, Apr. 29, 2008.

Government publications:

7. *Code of Federal Regulations*, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Part 121, pp. 270–290.
8. J. Dingell, "Letter to Democratic Caucus" (Washington, DC), Nov. 6. 2008.
9. S. 3633, US Senate, 110th Congress, 2nd Session (Washington, DC), Sept. 26, 2008.
10. US House Committee on Energy and Commerce, "Food and Drug Administration Globalization Act," Revised Discussion Draft, July 24, 2008 (Washington DC).
11. FDA, "Human and Veterinary Drugs, Good Manufacturing Practices and Proposed Exemptions for Certain OTC Products," *Fed. Regist.* **43** (190), 45013–45089 (Sept. 29, 1978).
12. ICH, Q1B *Photostability Testing of New Drug Substances and Products*, Step 2 version (1996).
13. FDA, *Guidance Title* (Rockville, MD, Nov. 2004).

Pharmacopeia:

14. *USP 27–NF 22* (US Pharmacopeial Convention, Rockville, MD, 2003), pp. X–X. (Note: N dash between USP and NF, numbers are not italicized but USP and NF are.)

Note if the above is the reference for an entire General Chapter or other **titled** section, then it follows the style as for the chapter in a book, referenced as follows:

15. *USP 30–NF 25* General Chapter <1231>, “Water for Pharmaceutical Purposes,” page–page.
16. USP Proposed General Test <429>, “Light Diffraction Measurement of Particle Size,” *Pharmacopeial Forum* **28** (4), 1293–1298.
17. *EurPh*, General Text 5.2.8 (EDQM, Strasbourg, France, YEAR), pp–pp.

Patents

18. Author or Company name, “Transmitter Switch for Wireless ID,” US patent 125356, Dec. 2003.

Online-only DOI articles

19. D. Trauner et al., “Biomimetic Synthesis of the IDO Inhibitors Exiguamine A and B,” *Nature Chem. Bio.* online, DOI:10.1038/nchembio.107, Aug. 1, 2008.

Other

- Federal Register
- ICH Q8 *Pharmaceutical Development*
- USP General Chapter <1078>
- Italicize USP when referring to the book, not the organization (National Formulary or “NF” is always italicized)
- Italicize titles of Guidelines and Guidances
- Critical Path Initiative (no italics)
- FDA’s Quality-by-Design and cGMPs for the 21st Century Initiative (no italics)
- Only include urls if critical to finding document online. If a url is included, do not include <http://> unless necessary and be sure to add an access date (e.g., “accessed May 9, 2009”) to the end of reference.

OTHER WAYS TO CONTRIBUTE TO PHARMACEUTICAL TECHNOLOGY

• Peer-Reviewed Papers, Case Studies, and Technical Notes

Please see our separate guidelines for authors for details.

Send submissions to Michelle Hoffman, Editorial Director, mhoffman@advanstar.com, and Angie Drakulich, Managing Editor, adrakulich@advanstar.com.

• Viewpoint/Opinion Articles & Blogs

Pharmaceutical Technology's Viewpoint column consists of 1000-word nonpromotional opinion pieces based on business or scientific rationale. Viewpoints are accompanied by authors' headshots. This section is not peer reviewed.

We also publish from time-to-time guest blog posts for our [blog](#), PharmTech Talk, which is updated daily at blog.PharmaTech.com.

Send submissions to Michelle Hoffman, Editorial Director, mhoffman@advanstar.com, and Angie Drakulich, Managing Editor, adrakulich@advanstar.com.

• Agent-In-Place Stories

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story to share, please send it to Control at AgentinPlace@advanstar.com. We won't use any names, but if we do use your tale, Control will send you a coveted *Pharmaceutical Technology* T-shirt.

• ePT—the Electronic Newsletter of *Pharmaceutical Technology*.

The early warning system for drug manufacturing, an easy-to-use weekly summary of drug-making, business, and regulatory news. *Send all news releases and product releases should be sent to via email to ptpress@advanstar.com*

• *Equipment & Processing Report* eNewsletter

Pharmaceutical Technology's Equipment & Processing Report is an electronic newsletter that keeps readers informed about manufacturing trends and equipment. It offers news analyses, discussions of manufacturing processes, equipment reviews, and regulatory coverage tied to GMP and PAT issues. *Send contributions to: Erik Greb, Assistant Editor, 732.346.3087, egreb@advanstar.com.*

• *Sourcing and Management* eNewsletter

Pharmaceutical Technology's Sourcing and Management, an electronic newsletter launched in 2005, offers original articles about managing pharmaceutical manufacturing. We cover best operating practices, insights on outsourcing, regulatory highlights, case histories, business developments, and new product data. Send submissions to Patricia Van Arnum Senior Editor, 732.346.3072, pvanarnum@advanstar.com.

**See also our separate PTSM author guidelines*